nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—NPY1R—Endothelin Pathways—ADCY10—nephrolithiasis	0.0783	0.149	CbGpPWpGaD
Atomoxetine—Epigastric discomfort—Hydrochlorothiazide—nephrolithiasis	0.0237	0.0591	CcSEcCtD
Atomoxetine—Sexual dysfunction—Hydrochlorothiazide—nephrolithiasis	0.0222	0.0555	CcSEcCtD
Atomoxetine—NPY1R—G alpha (i) signalling events—RGS14—nephrolithiasis	0.0138	0.0264	CbGpPWpGaD
Atomoxetine—HTR6—Monoamine GPCRs—CHRM3—nephrolithiasis	0.012	0.0229	CbGpPWpGaD
Atomoxetine—HTR1D—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0119	0.0227	CbGpPWpGaD
Atomoxetine—HTR1B—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0117	0.0222	CbGpPWpGaD
Atomoxetine—Sleep disorder—Hydrochlorothiazide—nephrolithiasis	0.0104	0.0261	CcSEcCtD
Atomoxetine—HTR6—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0101	0.0192	CbGpPWpGaD
Atomoxetine—HTR1D—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.01	0.0191	CbGpPWpGaD
Atomoxetine—Nasal congestion—Hydrochlorothiazide—nephrolithiasis	0.00992	0.0248	CcSEcCtD
Atomoxetine—HTR1B—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0098	0.0187	CbGpPWpGaD
Atomoxetine—Libido decreased—Hydrochlorothiazide—nephrolithiasis	0.00975	0.0243	CcSEcCtD
Atomoxetine—Hot flush—Hydrochlorothiazide—nephrolithiasis	0.00966	0.0241	CcSEcCtD
Atomoxetine—Menopausal symptoms—Hydrochlorothiazide—nephrolithiasis	0.00958	0.0239	CcSEcCtD
Atomoxetine—Thirst—Hydrochlorothiazide—nephrolithiasis	0.0095	0.0237	CcSEcCtD
Atomoxetine—Tolterodine—CHRM3—nephrolithiasis	0.00949	0.349	CrCbGaD
Atomoxetine—Disturbance in sexual arousal—Hydrochlorothiazide—nephrolithiasis	0.00897	0.0224	CcSEcCtD
Atomoxetine—Affect lability—Hydrochlorothiazide—nephrolithiasis	0.0089	0.0222	CcSEcCtD
Atomoxetine—HTR2C—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00884	0.0168	CbGpPWpGaD
Atomoxetine—CYP2C19—urine—nephrolithiasis	0.00875	0.183	CbGeAlD
Atomoxetine—Mood swings—Hydrochlorothiazide—nephrolithiasis	0.00856	0.0214	CcSEcCtD
Atomoxetine—Maprotiline—CHRM3—nephrolithiasis	0.00846	0.311	CrCbGaD
Atomoxetine—Abdominal pain upper—Hydrochlorothiazide—nephrolithiasis	0.00825	0.0206	CcSEcCtD
Atomoxetine—Breast disorder—Hydrochlorothiazide—nephrolithiasis	0.00817	0.0204	CcSEcCtD
Atomoxetine—Influenza—Hydrochlorothiazide—nephrolithiasis	0.00781	0.0195	CcSEcCtD
Atomoxetine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.00772	0.0147	CbGpPWpGaD
Atomoxetine—HTR2A—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00767	0.0146	CbGpPWpGaD
Atomoxetine—HTR2C—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00743	0.0142	CbGpPWpGaD
Atomoxetine—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.0073	0.0182	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Hydrochlorothiazide—nephrolithiasis	0.00726	0.0181	CcSEcCtD
Atomoxetine—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.00722	0.018	CcSEcCtD
Atomoxetine—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.00719	0.018	CcSEcCtD
Atomoxetine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00718	0.0137	CbGpPWpGaD
Atomoxetine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.00684	0.013	CbGpPWpGaD
Atomoxetine—Conjunctivitis—Hydrochlorothiazide—nephrolithiasis	0.00677	0.0169	CcSEcCtD
Atomoxetine—NPY1R—renal system—nephrolithiasis	0.0067	0.14	CbGeAlD
Atomoxetine—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.00653	0.0163	CcSEcCtD
Atomoxetine—HTR2A—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00645	0.0123	CbGpPWpGaD
Atomoxetine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00636	0.0121	CbGpPWpGaD
Atomoxetine—NPY1R—cortex of kidney—nephrolithiasis	0.00631	0.132	CbGeAlD
Atomoxetine—NPY1R—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00628	0.012	CbGpPWpGaD
Atomoxetine—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.00622	0.0155	CcSEcCtD
Atomoxetine—SLC6A4—NRF2 pathway—SLC2A9—nephrolithiasis	0.00602	0.0115	CbGpPWpGaD
Atomoxetine—Flushing—Hydrochlorothiazide—nephrolithiasis	0.0058	0.0145	CcSEcCtD
Atomoxetine—HTR2A—urine—nephrolithiasis	0.00558	0.117	CbGeAlD
Atomoxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00538	0.0103	CbGpPWpGaD
Atomoxetine—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.00536	0.0134	CcSEcCtD
Atomoxetine—Tension—Hydrochlorothiazide—nephrolithiasis	0.00534	0.0133	CcSEcCtD
Atomoxetine—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.00533	0.0133	CcSEcCtD
Atomoxetine—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.00529	0.0132	CcSEcCtD
Atomoxetine—Back pain—Hydrochlorothiazide—nephrolithiasis	0.00526	0.0132	CcSEcCtD
Atomoxetine—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00523	0.0131	CcSEcCtD
Atomoxetine—SLC6A2—NRF2 pathway—SLC2A9—nephrolithiasis	0.00518	0.00987	CbGpPWpGaD
Atomoxetine—CYP3A4—urine—nephrolithiasis	0.00517	0.108	CbGeAlD
Atomoxetine—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.00513	0.0128	CcSEcCtD
Atomoxetine—Tremor—Hydrochlorothiazide—nephrolithiasis	0.0051	0.0127	CcSEcCtD
Atomoxetine—CYP2D6—urine—nephrolithiasis	0.00509	0.106	CbGeAlD
Atomoxetine—Nortriptyline—CHRM3—nephrolithiasis	0.00508	0.187	CrCbGaD
Atomoxetine—HTR1D—G alpha (i) signalling events—RGS14—nephrolithiasis	0.00507	0.00966	CbGpPWpGaD
Atomoxetine—SLC6A2—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00506	0.00965	CbGpPWpGaD
Atomoxetine—Agitation—Hydrochlorothiazide—nephrolithiasis	0.005	0.0125	CcSEcCtD
Atomoxetine—HTR1B—G alpha (i) signalling events—RGS14—nephrolithiasis	0.00496	0.00946	CbGpPWpGaD
Atomoxetine—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.00489	0.0122	CcSEcCtD
Atomoxetine—Syncope—Hydrochlorothiazide—nephrolithiasis	0.00488	0.0122	CcSEcCtD
Atomoxetine—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00481	0.012	CcSEcCtD
Atomoxetine—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.00478	0.0119	CcSEcCtD
Atomoxetine—Cough—Hydrochlorothiazide—nephrolithiasis	0.00475	0.0119	CcSEcCtD
Atomoxetine—NPY1R—GPCR downstream signaling—RGS14—nephrolithiasis	0.00474	0.00903	CbGpPWpGaD
Atomoxetine—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.00463	0.0116	CcSEcCtD
Atomoxetine—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00463	0.0116	CcSEcCtD
Atomoxetine—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.00463	0.0116	CcSEcCtD
Atomoxetine—SLC6A2—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00463	0.00883	CbGpPWpGaD
Atomoxetine—SLC6A2—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00463	0.00883	CbGpPWpGaD
Atomoxetine—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.00462	0.0115	CcSEcCtD
Atomoxetine—SLC6A3—NRF2 pathway—SLC2A9—nephrolithiasis	0.00459	0.00874	CbGpPWpGaD
Atomoxetine—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.00453	0.0113	CcSEcCtD
Atomoxetine—SLC6A3—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00448	0.00855	CbGpPWpGaD
Atomoxetine—Shock—Hydrochlorothiazide—nephrolithiasis	0.00437	0.0109	CcSEcCtD
Atomoxetine—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00434	0.0108	CcSEcCtD
Atomoxetine—NPY1R—Signaling by GPCR—RGS14—nephrolithiasis	0.0043	0.0082	CbGpPWpGaD
Atomoxetine—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00429	0.0107	CcSEcCtD
Atomoxetine—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00423	0.0106	CcSEcCtD
Atomoxetine—Desipramine—CHRM3—nephrolithiasis	0.00418	0.154	CrCbGaD
Atomoxetine—SLC6A3—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.0041	0.00782	CbGpPWpGaD
Atomoxetine—SLC6A3—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.0041	0.00782	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR ligand binding—CHRM3—nephrolithiasis	0.0041	0.00781	CbGpPWpGaD
Atomoxetine—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00405	0.0101	CcSEcCtD
Atomoxetine—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00402	0.01	CcSEcCtD
Atomoxetine—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00399	0.00996	CcSEcCtD
Atomoxetine—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.00395	0.00986	CcSEcCtD
Atomoxetine—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00391	0.00977	CcSEcCtD
Atomoxetine—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00386	0.00965	CcSEcCtD
Atomoxetine—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00383	0.00957	CcSEcCtD
Atomoxetine—HTR6—G alpha (s) signalling events—PTH—nephrolithiasis	0.00381	0.00725	CbGpPWpGaD
Atomoxetine—Pain—Hydrochlorothiazide—nephrolithiasis	0.0038	0.00949	CcSEcCtD
Atomoxetine—Constipation—Hydrochlorothiazide—nephrolithiasis	0.0038	0.00949	CcSEcCtD
Atomoxetine—NPY1R—GPCR ligand binding—PTH—nephrolithiasis	0.00375	0.00714	CbGpPWpGaD
Atomoxetine—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00366	0.00914	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00363	0.00907	CcSEcCtD
Atomoxetine—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00353	0.00881	CcSEcCtD
Atomoxetine—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00351	0.00877	CcSEcCtD
Atomoxetine—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00351	0.00877	CcSEcCtD
Atomoxetine—SLC6A2—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00351	0.00669	CbGpPWpGaD
Atomoxetine—SLC6A2—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00351	0.00669	CbGpPWpGaD
Atomoxetine—HTR2A—GPCRs, Other—CHRM3—nephrolithiasis	0.00341	0.0065	CbGpPWpGaD
Atomoxetine—SLC6A2—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00326	0.00622	CbGpPWpGaD
Atomoxetine—SLC6A2—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00326	0.00622	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—DGKH—nephrolithiasis	0.0032	0.0061	CbGpPWpGaD
Atomoxetine—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00319	0.00796	CcSEcCtD
Atomoxetine—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00314	0.00785	CcSEcCtD
Atomoxetine—SLC6A3—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00311	0.00593	CbGpPWpGaD
Atomoxetine—SLC6A3—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00311	0.00593	CbGpPWpGaD
Atomoxetine—HTR2C—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00305	0.00582	CbGpPWpGaD
Atomoxetine—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00304	0.00759	CcSEcCtD
Atomoxetine—NPY1R—Signaling Pathways—ADCY10—nephrolithiasis	0.00299	0.0057	CbGpPWpGaD
Atomoxetine—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00294	0.00734	CcSEcCtD
Atomoxetine—SLC6A2—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00291	0.00554	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—DGKH—nephrolithiasis	0.00291	0.00554	CbGpPWpGaD
Atomoxetine—SLC6A3—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00289	0.00551	CbGpPWpGaD
Atomoxetine—SLC6A3—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00289	0.00551	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00289	0.0055	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00289	0.0055	CbGpPWpGaD
Atomoxetine—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00282	0.00705	CcSEcCtD
Atomoxetine—Rash—Hydrochlorothiazide—nephrolithiasis	0.0028	0.007	CcSEcCtD
Atomoxetine—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.0028	0.00699	CcSEcCtD
Atomoxetine—Headache—Hydrochlorothiazide—nephrolithiasis	0.00278	0.00695	CcSEcCtD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00273	0.0052	CbGpPWpGaD
Atomoxetine—HTR1D—kidney—nephrolithiasis	0.00266	0.0555	CbGeAlD
Atomoxetine—HTR2A—G alpha (q) signalling events—DGKH—nephrolithiasis	0.00265	0.00505	CbGpPWpGaD
Atomoxetine—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00264	0.00659	CcSEcCtD
Atomoxetine—SLC6A3—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00258	0.00491	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00257	0.0049	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00256	0.00487	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00256	0.00487	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—RGS14—nephrolithiasis	0.00254	0.00485	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—DGKH—nephrolithiasis	0.00237	0.00452	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00235	0.00449	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00235	0.00449	CbGpPWpGaD
Atomoxetine—HTR6—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00232	0.00441	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—CHRM3—nephrolithiasis	0.00231	0.00441	CbGpPWpGaD
Atomoxetine—HTR1D—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.0023	0.00438	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00228	0.00434	CbGpPWpGaD
Atomoxetine—HTR1B—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00225	0.00429	CbGpPWpGaD
Atomoxetine—HTR2C—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.00221	0.0042	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—PTH—nephrolithiasis	0.00212	0.00403	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—CHRM3—nephrolithiasis	0.0021	0.00401	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00208	0.00397	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00208	0.00397	CbGpPWpGaD
Atomoxetine—CYP2C19—Biological oxidations—SLC26A1—nephrolithiasis	0.00205	0.0039	CbGpPWpGaD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00198	0.00378	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00197	0.00376	CbGpPWpGaD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00197	0.00375	CbGpPWpGaD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00193	0.00367	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—PTH—nephrolithiasis	0.00192	0.00366	CbGpPWpGaD
Atomoxetine—HTR2A—G alpha (q) signalling events—CHRM3—nephrolithiasis	0.00192	0.00365	CbGpPWpGaD
Atomoxetine—CYP2D6—Biological oxidations—SLC26A1—nephrolithiasis	0.00188	0.00359	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00178	0.0034	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00178	0.0034	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—RGS14—nephrolithiasis	0.00175	0.00333	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—RGS14—nephrolithiasis	0.00173	0.00331	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00172	0.00327	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—DGKH—nephrolithiasis	0.00172	0.00327	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.00171	0.00327	CbGpPWpGaD
Atomoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00171	0.00325	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—RGS14—nephrolithiasis	0.0017	0.00324	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00166	0.00316	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00166	0.00316	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—RGS14—nephrolithiasis	0.00159	0.00303	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00158	0.00301	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00158	0.00301	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—RGS14—nephrolithiasis	0.00158	0.003	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—RGS14—nephrolithiasis	0.00154	0.00294	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—CHRM3—nephrolithiasis	0.00151	0.00288	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—CHRM3—nephrolithiasis	0.0015	0.00286	CbGpPWpGaD
Atomoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00148	0.00282	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00148	0.00282	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00148	0.00282	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00147	0.0028	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00147	0.0028	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—CHRM3—nephrolithiasis	0.00147	0.0028	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00146	0.00278	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—PTH—nephrolithiasis	0.00138	0.00263	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—PTH—nephrolithiasis	0.00137	0.00261	CbGpPWpGaD
Atomoxetine—HTR2A—renal system—nephrolithiasis	0.00137	0.0285	CbGeAlD
Atomoxetine—HTR1B—GPCR ligand binding—PTH—nephrolithiasis	0.00134	0.00256	CbGpPWpGaD
Atomoxetine—HTR2A—kidney—nephrolithiasis	0.00132	0.0276	CbGeAlD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00131	0.0025	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00131	0.0025	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—RGS14—nephrolithiasis	0.00129	0.00245	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00127	0.00242	CbGpPWpGaD
Atomoxetine—CYP3A4—renal system—nephrolithiasis	0.00126	0.0264	CbGeAlD
Atomoxetine—CYP2D6—renal system—nephrolithiasis	0.00124	0.026	CbGeAlD
Atomoxetine—NPY1R—Signaling Pathways—CHRM3—nephrolithiasis	0.00124	0.00237	CbGpPWpGaD
Atomoxetine—CYP3A4—Biological oxidations—SLC26A1—nephrolithiasis	0.00123	0.00235	CbGpPWpGaD
Atomoxetine—CYP3A4—kidney—nephrolithiasis	0.00122	0.0255	CbGeAlD
Atomoxetine—CYP2D6—kidney—nephrolithiasis	0.0012	0.0251	CbGeAlD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00118	0.00225	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—DGKH—nephrolithiasis	0.00118	0.00225	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—DGKH—nephrolithiasis	0.00117	0.00223	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—RGS14—nephrolithiasis	0.00117	0.00223	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—DGKH—nephrolithiasis	0.00115	0.00219	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—PTH—nephrolithiasis	0.00114	0.00216	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—RGS14—nephrolithiasis	0.00112	0.00213	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—CHRM3—nephrolithiasis	0.00111	0.00212	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—ADCY10—nephrolithiasis	0.0011	0.0021	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—ADCY10—nephrolithiasis	0.00109	0.00209	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—DGKH—nephrolithiasis	0.00107	0.00204	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ADCY10—nephrolithiasis	0.00107	0.00204	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—DGKH—nephrolithiasis	0.00106	0.00203	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00105	0.00199	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—DGKH—nephrolithiasis	0.00104	0.00199	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—PTH—nephrolithiasis	0.00102	0.00194	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—RGS14—nephrolithiasis	0.00102	0.00194	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—CHRM3—nephrolithiasis	0.000966	0.00184	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—RGS14—nephrolithiasis	0.000938	0.00179	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—RGS14—nephrolithiasis	0.000931	0.00177	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—RGS14—nephrolithiasis	0.000911	0.00174	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—PTH—nephrolithiasis	0.000884	0.00168	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—DGKH—nephrolithiasis	0.00087	0.00166	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000854	0.00163	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000847	0.00161	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—CHRM3—nephrolithiasis	0.00083	0.00158	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ADCY10—nephrolithiasis	0.000812	0.00155	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—DGKH—nephrolithiasis	0.00079	0.00151	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—PTH—nephrolithiasis	0.000781	0.00149	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—CHRM3—nephrolithiasis	0.000775	0.00148	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—PTH—nephrolithiasis	0.000775	0.00148	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—CHRM3—nephrolithiasis	0.000769	0.00147	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—PTH—nephrolithiasis	0.000759	0.00145	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—DGKH—nephrolithiasis	0.000755	0.00144	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—CHRM3—nephrolithiasis	0.000753	0.00144	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—PTH—nephrolithiasis	0.000709	0.00135	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ADCY10—nephrolithiasis	0.000705	0.00134	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—PTH—nephrolithiasis	0.000704	0.00134	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—RGS14—nephrolithiasis	0.000691	0.00132	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—PTH—nephrolithiasis	0.000689	0.00131	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—DGKH—nephrolithiasis	0.000686	0.00131	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000633	0.00121	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—DGKH—nephrolithiasis	0.000633	0.00121	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000629	0.0012	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—DGKH—nephrolithiasis	0.000629	0.0012	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000629	0.0012	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—DGKH—nephrolithiasis	0.000615	0.00117	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000615	0.00117	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—RGS14—nephrolithiasis	0.0006	0.00114	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—PTH—nephrolithiasis	0.000575	0.0011	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CHRM3—nephrolithiasis	0.000571	0.00109	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—SPP1—nephrolithiasis	0.00057	0.00109	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000546	0.00104	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—PTH—nephrolithiasis	0.000522	0.000995	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—PTH—nephrolithiasis	0.000499	0.000952	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CHRM3—nephrolithiasis	0.000496	0.000945	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—DGKH—nephrolithiasis	0.000466	0.000889	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000466	0.000889	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GRHPR—nephrolithiasis	0.000462	0.000881	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CHRM3—nephrolithiasis	0.000458	0.000873	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CHRM3—nephrolithiasis	0.000454	0.000866	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PTH—nephrolithiasis	0.000453	0.000864	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CHRM3—nephrolithiasis	0.000445	0.000848	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GRHPR—nephrolithiasis	0.000425	0.00081	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PTH—nephrolithiasis	0.000419	0.000798	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PTH—nephrolithiasis	0.000416	0.000792	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—AGXT—nephrolithiasis	0.000412	0.000785	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PTH—nephrolithiasis	0.000407	0.000776	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000405	0.000772	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—DGKH—nephrolithiasis	0.000405	0.000772	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—AGXT—nephrolithiasis	0.000379	0.000722	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—SLC26A1—nephrolithiasis	0.00035	0.000668	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—APRT—nephrolithiasis	0.00035	0.000668	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CHRM3—nephrolithiasis	0.000337	0.000643	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—SLC26A1—nephrolithiasis	0.000322	0.000614	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—APRT—nephrolithiasis	0.000322	0.000614	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PTH—nephrolithiasis	0.000308	0.000588	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CHRM3—nephrolithiasis	0.000293	0.000558	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GRHPR—nephrolithiasis	0.000278	0.00053	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PTH—nephrolithiasis	0.000268	0.000511	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—AQP1—nephrolithiasis	0.00025	0.000476	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—AGXT—nephrolithiasis	0.000248	0.000472	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—AQP1—nephrolithiasis	0.00023	0.000438	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CHRM3—nephrolithiasis	0.000226	0.00043	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—APRT—nephrolithiasis	0.000211	0.000402	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SLC26A1—nephrolithiasis	0.000211	0.000402	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SPP1—nephrolithiasis	0.00021	0.000401	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SPP1—nephrolithiasis	0.000209	0.000398	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CHRM3—nephrolithiasis	0.000208	0.000396	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SPP1—nephrolithiasis	0.000204	0.000389	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SPP1—nephrolithiasis	0.000155	0.000295	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—AQP1—nephrolithiasis	0.00015	0.000286	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CHRM3—nephrolithiasis	0.000136	0.000259	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SPP1—nephrolithiasis	0.000134	0.000256	CbGpPWpGaD
